Global Uveitis Market - 2023-2030

Market Overview

The global uveitis market size was valued at US$ 456 million in 2022 and is estimated to reach US$ 837 million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).

Uveitis is an eye inflammation, which affects the middle layer of the tissue in the eyewall. The majority of the alter lie in the population ages of 20 to 50 years. Uveitis can sometimes be a serious issue that can also lead to loss of vision.

Market Dynamics

The major factors driving the global uveitis market are the rising demand for uveitis owing to increasing incidences of ophthalmic disorders such as uveitis glaucoma and uveitis cataract, surging awareness initiatives, advancements in technologies leading to the development of new drugs and novel product launches.

The increasing product pipeline of pharma companies and rising technological advancements leading to the development of new drugs are expected to drive the market's growth.

The uveitis market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of ophthalmic disorders such as uveitis glaucoma, uveitis cataract, AMD and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.

The uveitis medications are used widely for treatment purpose. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce uveitis medication products such as eye drops, injections, pills or implants. The market for these medications is increasing worldwide due to the enhanced number of these ophthalmic disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives related to these uveitis medications contribute to the market's growth. For instance, in November 1, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has been granted reimbursement for ILUVIEN (fluocinolone acetonide intravitreal implant) which is a sustained release intravitreal implant indicated for non-infectious uveitis, via Medis Pharmaceutical Company, its distribution partner.

High cost associated with the treatment and high risk of side effects are expected to hamper the market's growth.

Strict rules and regulations for the approval of medications utilized for uveitis is the major factor hindering the growth of the uveitis market. Various requirements, clinical trials must be fulfilled, leading to an increase in the overall cost of these medications. The high cost associated with these treatments is likely to hinder the growth.

High risk related to side effects of these medications is also limiting market's growth. Market recalls are also a leading factor restraining the growth of the market. Several recalls are taking place due to leakage or complications in implants.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The uveitis market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in October 17, 2022, Kiora Pharmaceuticals, Inc. announced its results from KIO-100 (formerly PP-001) Phase 1 study, showing its potential for non-infectious uveitis, an ophthalmic inflammatory disease treatment.

Segment Analysis

The anterior uveitis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The anterior uveitis segment is the highest market holder in the global uveitis market. The global uveitis market is segmented based on disease type as anterior uveitis, intermediate uveitis, posterior uveitis and pan uveitis. The anterior uveitis segment is the largest market shareholder due to its increasing number of incidences globally, increasing technological advancements and novel product launches.

Anterior uveitis is the most common kind of uveitis which mostly affects the ciliary body and the inside of the front of eye (between the iris and the cornea). It is also also known as iritis. Anterior uveitis can be caused due to a trauma to the eye, like getting hit in the eye or having a foreign particle in the eye. It is also linked with common health problems including syphilis, rheumatoid arthritis, tuberculosis and viral (herpes simplex). Its symptoms include blurred vision, red or inflamed eye, small, irregular-shaped pupil and sensitivity to light.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market's growth. For instance, in March 28, 2022, Bausch + Lomb, Bausch Health Companies' eye health business and Clearside Biomedical, Inc. a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS) announced the commercial launch of XIPERE (triamcinolone acetonide injectable suspension) in U.S., the first therapy which got approval for suprachoroidal use by the U.S. Food and Drug Administration (FDA) for the macular edema associated with uveitis treatment.

Geographical Analysis

North America holds the largest market share in the global uveitis market.

North America dominates the global uveitis market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of uveitis medications in several ophthalmic conditions like uveitis glaucoma or uveitis cataract, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the uveitis market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in August 8, 2022, Clearside Biomedical, Inc., a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS), announced about entering into a sale agreement with HealthCare Royalty Partners.

Competitive Landscape

The uveitis market is highly competitive with local and global companies' presence. Novartis Inc., AbbVie, Johnson & Johnson Services, Inc., Amgen, Alimera Sciences, Bausch & Lomb Incorporated., Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals, Inc., Clearside Biomedical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in September 23, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced its agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), to support and provide ILUVIEN (fluocinolone acetonide intravitreal implant) intravitreal implant for "A randomized clinical trial evaluating fluocinolone acetonide intravitreal implants or intravitreal faricimab injections vs due to Radiation Retinopathy visual acuity loss prevention observation.

Novartis AG

Overview: Novartis is engaged in discovering, developing, manufacturing, and selling a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Durezol: It is a topical corticosteroid which is indicated for pain and inflammation treatment linked with ocular surgery and endogenous anterior uveitis treatment.

Key Development: In June 17, 2022, Sandoz, a generic and biosimilar medicines provider, announced about application acceptance for high concentration formulation of its biosimilar Hyrimoz (adalimumab) by the European Medicines Agency (EMA) for regulatory review. The application covers all indications, including rheumatoid arthritis, uveitis, Crohn's disease, ulcerative colitis and plaque psoriasis

The global uveitis market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.